NFASC and neoplasm: Anti‐mouse VEGFXXX/NF antibodies significantly slowed the growth of experimental tumours generated with 786‐O cells by 56%, while the size of tumours in bevacizumab‐treated mice was similar to that of the control group, as previously described [46] (Fig. 5B).